A Study of KK2269 in Adult Participants With Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Mayo Clinic Arizona, Scottsdale, Arizona City Of Hope National Medical Center, Duarte, California Hoag Memorial Hospital Presbyterian, Newport Beach, California Mayo Clinic Jacksonville, Jacksonville, Florida Washington University, St Louis, Missouri The University of Texas Southwestern Medical Center, Dallas, Texas University of Washington, Seattle, Washington Japan
Aichi Cancer Center, Nagoya, Aichi-ken National Cancer Center Hospital East, Kashiwa, Chiba National Cancer Center Hospital, Chuo-ku, Tokyo Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo Last updated January 2026